Innovative Treatments for Tardive Dyskinesia

Released On
July 31, 2018

Expires On
July 31, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Psychology, Psychiatry, Physicians

Topic(s)
Tardive Dyskinesia

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and Global Medical Education.

 

This activity is supported by an independent educational grant from Neurocrine Biosciences, Sunovion and Shire.

 

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.0 contact hour(s) (0.10 CEUs).
  • Psychologists — 1.0 continuing education credits.
  • Nurses — 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, pharmacists, registered nurses, psychologists and other healthcare professionals engaged in the care of patients with psychiatric illnesses.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the prevalence and diagnostic criteria for TD in psychiatric patients.
  • Be familiar with the AIMS examination for TD.
  • Use evidence based treatments for treatingTD, considering both efficacy and tolerability.

Faculty

Thomas L. Schwartz, M.D.

Professor of Psychiatry and Director of Adult Psychiatric Clinical Services
SUNY Upstate Medical University

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-18-321-H01-P
Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Psychologist Continuing Education

Postgraduate Institute for Medicine (PIM) is approved by the American Psychological Association to sponsor continuing education for psychologists. PIM maintains responsibility for this program and its content.

Credit Designation

This program offers a maximum of 1.0 continuing education credits for psychologists.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Thomas Schwartz, MD

  • Royalties: Taylor & Francis, Routledge, Cambridge University Press

Planners and Managers

Prakash Masand, MD, GME Planner and Manager

  • Consulting Fees: Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, Takeda
  • Research Support: Allergan, Merck
  • Speaker’s Bureau: Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, Takeda

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.